Summary
The Supreme Court has criticised the wide gaps between the price to retailer (PTR) and the maximum retail price (MRP) of certain drugs, including cancer medicines, which in some instances reach 1,000%. Because these drugs are not sold over the counter, hospitals effectively choose the brand, so manufacturers compete by inflating MRPs and offering hospitals low PTRs, leaving the difference as an embedded reward.
The debate now is whether to cap trade margins, as the 2019 Trade Margin Rationalisation did for 42 anti-cancer drugs or to fix the market failure without setting prices.
WHY IN NEWS FOR UPSC & STATE PCS
The Supreme Court is hearing public interest litigation on capping trade margins of drugs and medical consumables sold by private hospitals and has suggested a fixed percentage markup across drugs. The scrutiny follows Competition Commission findings that some private hospitals force patients to buy from their own pharmacies and concerns flagged by drug regulators in Karnataka and Maharashtra about the financial strain on patients.
Standard News
A Market Where the Buyer Never Chooses
Most markets discipline prices because buyers can walk away. Hospital drugs break that rule. A patient admitted for cancer treatment does not pick the brand; the hospital does. That single fact turns the usual logic of competition upside down and it is why the Supreme Court's scrutiny of PTR-MRP gaps of up to 1,000% matters.
How the Inverted Competition Works
- Manufacturers are not competing to win patients. They are competing to win hospitals.
- The way to win a hospital is not a lower price. It is a wider gap: a high printed MRP paired with a low price to the hospital.
- The hospital keeps the difference and has every reason to stock the brand with the largest gap.
- Where hospitals also require patients to buy from in-house pharmacies
- something Competition Commission investigators have documented - the patient cannot even shop around.
The Real Tension
For capping margins: the 2019 experiment proved the gap was compressible. When the NPPA capped trade margins on 42 anti-cancer drugs at 30%, prices of 526 brands fell by up to 91%. Nothing about the drugs changed - only the margin.
For leaving prices to the market: price controls are blunt. A single fixed markup across thousands of drugs ignores real differences in storage, wastage and handling costs and invites hospitals to recover lost margin elsewhere - in room charges or procedure fees.
The deeper fault is captivity, the argument goes, so fix captivity and let competition do the rest. Both arguments are serious. Neither alone is enough.
TAN's Position
TAN's position is that trade margins on hospital-dispensed critical drugs should be capped, but through a regressive (tapered) margin rather than one flat percentage and alongside strict competition enforcement against captive pharmacies. The reason for a tapered design is simple arithmetic.
A flat 30% markup earns a hospital far more in rupees on an expensive drug than on a cheap one, so a flat cap still rewards choosing the costlier brand. A margin whose percentage falls as the price rises removes that incentive.
The reason for pairing it with competition action is that a cap treats the symptom. Letting patients buy outside the hospital treats the cause. What would change our view: clear evidence that capped drugs were withdrawn or became scarce after 2019.
Without that evidence, the case for capping is stronger than the case for waiting.
Quick Facts
Key numbers & takeaways — revise these first
-
PTR (price to retailer) is what the seller pays the manufacturer; MRP is the maximum price charged to the patient.
-
2.
-
The Supreme Court flagged PTR-MRP gaps of up to 1,000% in some instances.
-
3.
-
In February 2019, the NPPA capped the trade margin of 42 non-scheduled anti-cancer drugs at 30%.
-
4.
-
Prices of 526 brands fell by up to 91% after the 2019 Trade Margin Rationalisation, as reported by the Department of Pharmaceuticals.
-
5.
-
NPPA functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
-
6.
-
The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955.
-
7.
-
Section 4 of the Competition Act, 2002 prohibits abuse of a dominant position.
-
8.
-
Related litigation: Siddharth Dalmia vs Union of India.
Connect the dots for your UPSC preparation.
Standard news covers the event. Log in to read our comprehensive analysis and uncover the hidden constitutional, structural, and ethical dimensions of this topic:
The full-strength case against capping margins, including the cross-subsidy and margin-shifting arguments that make price controls genuinely risky.
Why a flat percentage cap still rewards expensive brands, worked through with the arithmetic of a regressive margin.
How the Competition Act's abuse-of-dominance route against captive pharmacies attacks the cause rather than the symptom.
The specific evidence that would make TAN reverse its position and why the 2019 Trade Margin Rationalisation shifts the burden of proof.
Included in this analysis
Join thousands of aspirants analyzing the news deeply.
Unlock Premium — Rs.699 AnnuallyDon't have an account? Sign up for free